Tarsus Pharmaceuticals, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $TARS in the last 7 days.
No SEC Form 4 filings for $TARS in the last 30 days.
See all $TARS insider activity →ETFs were net buyers of Tarsus Pharmaceuticals (TARS) on Oct. 16, with $89.4 million in net inflows. FBT was the largest buyer, adding $90.7 million worth of shares. TARS has a market cap of $3.4 billion and reported $606.3 million in trailing 12-month revenue, up 90.9%. The stock is down 15.12% year to date.
Analysts from Barclays and J.P. Morgan maintained Buy ratings on Merck (MRK), Tarsus Pharmaceuticals (TARS), and Ascendis Pharma (ASND). MRK has a $150 PT from Barclays, $180 from Scotiabank. TARS has a $110 PT from Barclays, $116 from Goldman Sachs. ASND has a $318.31 avg PT. All stocks have upside potential according to analysts.
Oppenheimer's Fall 2026 SMID-cap stock picks include four Strong Buy-rated companies: Semtech (SMTC, 4.96), Onto Innovation (ONTO, 4.83), Life Time Group (LTH, 4.72), and Pursuit Attractions (PRSU, 4.61). The remaining nine stocks received Hold ratings, with scores ranging from 3.48 to 2.78. Seeking Alpha's Quant Rating system evaluates stocks on valuation, growth, profitability, and momentum.
Recent TARS coverage spans financial news, insider activity and mergers & acquisitions.
ETF buying suggests short‑term support for the stock.
New analyst coverage and higher targets point to potential gains for TARS.
Bearish rating could weigh on the stock.
Buy rating with a higher target may encourage modest buying.
Analyst upgrade may lift the stock toward the new target.
AlphAI scores every news story that mentions TARS with an AI model for sentiment and relevance, and aggregates insider trades from Tarsus Pharmaceuticals, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
ETFs were net buyers of Tarsus Pharmaceuticals (TARS) on Oct. 16, with $89.4 million in net inflows. FBT was the largest buyer, adding $90.7 million worth of shares. TARS has a market cap of $3.4 billion and reported $606.3 million in trailing 12-month revenue, up 90.9%. The stock is down 15.12% year to date.
1 min readAnalysts from Barclays and J.P. Morgan maintained Buy ratings on Merck (MRK), Tarsus Pharmaceuticals (TARS), and Ascendis Pharma (ASND). MRK has a $150 PT from Barclays, $180 from Scotiabank. TARS has a $110 PT from Barclays, $116 from Goldman Sachs. ASND has a $318.31 avg PT. All stocks have upside potential according to analysts.
2 min readOppenheimer's Fall 2026 SMID-cap stock picks include four Strong Buy-rated companies: Semtech (SMTC, 4.96), Onto Innovation (ONTO, 4.83), Life Time Group (LTH, 4.72), and Pursuit Attractions (PRSU, 4.61). The remaining nine stocks received Hold ratings, with scores ranging from 3.48 to 2.78. Seeking Alpha's Quant Rating system evaluates stocks on valuation, growth, profitability, and momentum.
2 min readAnalysts updated ratings for healthcare companies. TD Cowen maintained a Buy rating on TransMedics Group (TMDX) with a $120 target. Regeneron (REGN) was kept at Hold by Leerink Partners. Oppenheimer maintained a Buy rating on Tarsus Pharmaceuticals (TARS) with a $100 target. All have consensus ratings and price targets.
2 min readGoldman Sachs initiated coverage of Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy rating and $116.00 price target. The company's stock trades at $74.29 with a $3.26B market cap. Tarsus reported Q2 2026 sales of $173.9M, beating estimates, and raised full-year Xdemvy sales guidance. Jefferies raised its price target to $105, citing strong prescription data.
2 min readLINK WILLIAM J PHD sold 12,500 shares of Tarsus Pharmaceuticals, Inc. (TARS) at an average of $78.38 ($78.33–$80.01, $0.98M total) across 3 trades on 2026-09-15 under a Rule 10b5-1 trading plan.
1 min readBarclays reinstated Tarsus Pharmaceuticals (TARS) with an Overweight rating and a $110.00 price target. The company's stock is currently trading at $78.23, with a GF Value™ of $160.86, indicating a 51.4% undervaluation. TARS has a GF Score™ of 46/100, reflecting mixed financial health and performance. The company focuses on biotechnology, particularly eye care, with its lead product being XDEMVY.
2 min readTarsus Pharmaceuticals, Inc. (TARS) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care September 4, 2026 Adds gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt’s disease, a pote
2 min readAzamian Bobak R. (President/CEO and Board Chair) sold 10,000 indirectly-held shares of Tarsus Pharmaceuticals, Inc. (TARS) at an average of $90.56 ($90.27–$91.27, $0.91M total) across 2 trades on 2026-09-04 under a Rule 10b5-1 trading plan.
1 min readLin Elizabeth Yeu (Chief Medical Officer) sold 10,773 shares of Tarsus Pharmaceuticals, Inc. (TARS) at an average of $87.50 ($85.00–$90.00, $0.94M total) across 2 trades on 2026-09-04 under a Rule 10b5-1 trading plan.
1 min read
